

<b>Examiner-Initiated Interview Summary</b>		<b>Application No.</b> 10/767,638	<b>Applicant(s)</b> CHARIFSON ET AL.
<b>Examiner</b> Celia Chang		<b>Art Unit</b> 1625	

  

**All Participants:**

(1) Celia Chang.

(2) Michael C Badia.

**Date of Interview:** 26 June 2008

**Type of Interview:**

☒ Telephonic

☐ Video Conference

☐ Personal (Copy given to: ☐ Applicant ☐ Applicant's representative)

Exhibit Shown or Demonstrated: ☐ Yes ☐ No

If Yes, provide a brief description:

**Status of Application:** \_\_\_\_\_

(3) \_\_\_\_\_

(4) \_\_\_\_\_

**Time:** \_\_\_\_\_

  

**Part I.**

Rejection(s) discussed:

112 first paragraph

Claims discussed:

21,26,28, 29,32

Prior art documents discussed:

  

**Part II.**

**SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:**

*See Continuation Sheet*

  

**Part III.**

☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.

☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.

  

/Celia Chang/

Primary Examiner, Art Unit 1625

(Applicant/Applicant's Representative Signature – if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed: The compounds were disclosed to have efficacy on page 48 section [00135] which should be incorporated into the claims. An examiner's amendment was authorized to cancel claims 26, 28, 29, 32 amend claim 21 and added new claims 33-35 employing the scope of page 48,.